Association of ErbB2 Ser1113 phosphorylation with epidermal growth factor receptor co-expression and poor prognosis in human breast cancer

Molecular and Cellular Biochemistry

Volumn 218, Issue 1-2, 2001, Pages 47-54

  Ouyang, X ^a   Gulliford, T ^a   Zhang, H ^a   Smith, G ^a   Huang, G ^a   Epstein, R J ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Desensitization; ErbB2; Phosphoserine; Protein tyrosine kinases

Indexed keywords

BIOCHEMICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; MONOCLONAL ANTIBODY; ONCOPROTEIN; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; SERINE; TYROSINE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FORSKOLIN; PHORBOL DIBUTYRATE; PHOSPHOSERINE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; PLATELET-DERIVED GROWTH FACTOR BB; VANADIC ACID;

ANIMAL CELL; ARTICLE; BREAST CANCER; CELL STRAIN 3T3; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PROGNOSIS; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; ANIMAL; BREAST TUMOR; CELL CULTURE; CONFOCAL MICROSCOPY; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC TRANSFECTION; IMMUNOBLOTTING; IMMUNOLOGY; METABOLISM; MORTALITY; PHOSPHORYLATION;

ANIMALIA;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELLS, CULTURED; EPIDERMAL GROWTH FACTOR; FLUORESCENT ANTIBODY TECHNIQUE; FORSKOLIN; HUMANS; IMMUNOBLOTTING; MICE; MICROSCOPY, CONFOCAL; PHORBOL 12,13-DIBUTYRATE; PHOSPHORYLATION; PHOSPHOSERINE; PLATELET-DERIVED GROWTH FACTOR; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TRANSFECTION; VANADATES;

EID: 0034745034     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007249004222     Document Type: Article

References (33)

1. Platelet-derived growth factor mimics phorbol diester action on epidermal growth factor receptor phosphorylation at threonine-654
2. Tumor-promoting phorbol diesters cause the phosphorylation of epidermal growth factor receptors in normal human fibroblasts at threonine-654
3. Protein kinase C phosphorylation at Thr 654 of the unoccupied EGF receptor and EGF binding regulate functional receptor loss by independent mechanisms
4. Multisite phosphorylation of the epidermal growth factor receptor: Use of site-directed mutagenesis to examine the role of serine/threonine phosphorylation
5. Mechanism of desensitization of the epidermal growth factor receptor protein-tyrosine kinase
6. GM3 directly inhibits tyrosine phosphorylation and de-N-acetyl-GM3 directly enhances serine phosphorylation of epidermal growth factor receptor, independently of receptor-receptor interaction
7. Okadaic acid-induced hyperphosphorylation of the epidermal growth factor receptor
8. Epidermal growth factor receptor cytoplasmic domain mutations trigger ligand-independent transformation
9. Increased oncogenic potential of ErbB is associated with the loss of a COOH-terminal domain serine phosphorylation site
10. Signal transduction by the epidermal growth factor receptor is attenuated by a COOH-terminal domain serine phosphorylation site
11. HER-2/erbB2 is phosphorylated by calmodulin-dependent protein kinase II on a single site in the cytoplasmic tail at threonine-1172
12. Synthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB-2 receptor
13. Proxy activation of ErbB2 by heterologous ligands suggests a heterotetrameric mechanism of receptor tyrosine kinase interaction
14. Preferential detection of catalytically inactive c-erbB-2 by antibodies to unphoshorylated peptides mimicking receptor tyrosine autophosphorylation sites
15. Reduced ability of transforming growth factor-alpha to induce hetero-oligomerization and downregulation of EGFR suggests a mechanism of oncogenic synergy with ErbB2
16. Adjacent carboxy-terminal tyrosine phosphorylation events identify functionally distinct ErbB2 receptor subsets
17. Human cancer cells exhibit protein kinase C-dependent c-erbB-2 transmodulation which correlate with phosphatase sensitivity and kinase activity
18. r tumour antigen
19. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications
20. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
21. Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene
22. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation
23. Immunodetection of the ligand-activated receptor for epidermal growth factor
24. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
25. Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: A mechanism of interreceptor kinase activation and transphosphorylation
26. Overexpression of ErbB2 impairs downregulation of epidermal growth factor receptors via a post-transcriptional mechanism
27. Superagonistic behaviour of epidermal growth factor/transforming growth factor-alpha chimeras: Correlation with receptor routing after ligand-induced internalization
28. Transforming growth factor-alpha short-circuits downregulation of the epidermal growth factor receptor
29. Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer
30. ras activation
31. Serine 1002 is a site of in vivo and in vitro phosphorylation of the epidermal growth factor receptor
32. EGF receptor binding and transformation by v-cbl is ablated by the introduction of a loss-of-function mutation from the Caenorhabditis elegans sli-1 gene
33. Detection of ErbB2 oversignalling in a majority of breast cancers with phosphorylation-state-specific antibodies